High Sensitivity C-Reactive Protein (Hs-CRP) is a key biomarker for detecting inflammation, which is linked to cardiovascular risks. Monitoring your Hs-CRP levels can help prevent chronic diseases before symptoms appear. Elevated Hs-CRP is a stronger predictor of heart attacks than cholesterol. Lifestyle factors like obesity and smoking can increase Hs-CRP. Regular testing empowers you to make informed health decisions.
High Sensitivity C-Reactive Protein (Hs-CRP) is a key biomarker for detecting inflammation, which is linked to cardiovascular risks. Monitoring your Hs-CRP levels can help prevent chronic diseases before symptoms appear. Elevated Hs-CRP is a stronger predictor of heart attacks than cholesterol. Lifestyle factors like obesity and smoking can increase Hs-CRP. Regular testing empowers you to make informed health decisions.
Inflammatory Response Pathway
Hs-CRP is produced in the liver in response to inflammation, primarily triggered by interleukin-6. This pathway is crucial in the body's defense mechanism against infections and injuries.
Body systems: Immune System, Liver
Cardiovascular Risk Pathway
Elevated hs-CRP levels are linked to increased cardiovascular risk, as inflammation contributes to atherosclerosis and plaque formation in arteries.
Body systems: Cardiovascular System
Metabolic Syndrome Pathway
Hs-CRP levels rise with metabolic syndrome components such as obesity and insulin resistance, indicating a systemic inflammatory state.
Body systems: Endocrine System, Metabolic System
Understanding Hs-CRP levels is crucial as they reflect inflammation, a precursor to many chronic conditions. Elevated levels can indicate heightened risk for cardiovascular diseases, making early intervention possible.
Cardiovascular Disease
elevatedHigh hs-CRP levels are a strong predictor of cardiovascular events, even more so than high cholesterol.
Type 2 Diabetes
elevatedChronic inflammation indicated by elevated hs-CRP can contribute to insulin resistance, a precursor to type 2 diabetes.
Stroke
elevatedIncreased hs-CRP levels are associated with a higher risk of stroke due to inflammation-related vascular damage.
Obesity
monitorObesity can elevate hs-CRP levels, reflecting systemic inflammation that may lead to further health complications.
Chronic Inflammatory Conditions
monitorPersistent high hs-CRP levels can indicate ongoing inflammation, common in conditions like rheumatoid arthritis.
Reference ranges may vary slightly between laboratories. The values below represent commonly accepted clinical ranges.
Ranges shown are general guidelines. Consult your provider for personalized interpretation.
| Biomarker | Reference range | Interpretation |
|---|---|---|
Hs Crp (Male — Optimal) | 0–0.55 mg/L | Target range for optimal health |
Hs Crp (Female — Optimal) | 0–1 mg/L | Target range for optimal health |
Hs Crp (Male — Standard) | 0–1 mg/L | Standard lab reference range |
Hs Crp (Female — Standard) | 0–1 mg/L | Standard lab reference range |
Levels in this range indicate a moderate risk of inflammation-related conditions. Further investigation and lifestyle adjustments are recommended.
Moderate Risk Indicator: Elevated levels may suggest an increased risk of cardiovascular events and warrant closer monitoring.
Associated Conditions: Higher Hs-CRP levels have been linked to obesity, diabetes, and hypertension.
Consider consulting with a healthcare provider to explore underlying causes and preventive strategies.
Low Hs Crp levels below the standard range may indicate an underlying health condition that warrants further evaluation.
Goal: Reduce inflammation and maintain optimal Hs-CRP levels. | Timeline: 6 months
Initial Assessment(Month 1)
Identify baseline Hs-CRP levels and lifestyle factors contributing to inflammation.
Lifestyle Modification(Months 2-4)
Implement dietary and lifestyle changes to reduce inflammation.
Ongoing Monitoring(Months 5-6)
Track progress and adjust strategies as needed to maintain optimal levels.
Goal: Optimize cardiovascular health by managing Hs-CRP levels. | Timeline: 12 months
Risk Evaluation(Month 1)
Assess cardiovascular risk factors and Hs-CRP levels to establish a baseline.
Targeted Intervention(Months 2-8)
Implement targeted interventions to reduce cardiovascular risk.
Maintenance and Prevention(Months 9-12)
Sustain improvements and prevent future cardiovascular events.
Goal: Enhance metabolic health by managing inflammation and Hs-CRP levels. | Timeline: 9 months
Comprehensive Evaluation(Month 1)
Evaluate metabolic health and inflammation markers to identify risk factors.
Metabolic Intervention(Months 2-6)
Implement strategies to improve metabolic health and reduce inflammation.
Long-term Management(Months 7-9)
Maintain metabolic health improvements and prevent relapse into high-risk states.
Retesting may be advised if initial results are elevated, especially if there are changes in symptoms or risk factors. Consult your healthcare provider for personalized guidance.
Testing method: The hs-CRP test uses a high-sensitivity assay to detect low levels of C-reactive protein in the blood, providing a more precise measurement of inflammation compared to standard CRP tests. Results are typically available within 24-48 hours.
Baseline: A 52-year-old postmenopausal woman presented with elevated Hs-CRP levels of 3.2 mg/L (standard range: 0.00 - 1.00 mg/L). She reported mild fatigue and a family history of cardiovascular disease. Her BMI was 28 kg/m², and blood pressure was 140/90 mmHg.
Interventions:
Progress: After 12 weeks, Hs-CRP levels decreased to 1.5 mg/L, a reduction of 53%. Blood pressure improved to 130/85 mmHg, and BMI reduced to 27 kg/m². The patient reported increased energy levels and improved mood.
Key takeaway: The case highlights the effectiveness of lifestyle modifications in reducing inflammation markers. Limitations include the absence of a control group and reliance on self-reported adherence. Results align with existing literature on diet and exercise benefits.
Baseline: A 45-year-old male with a BMI of 32 kg/m² and Hs-CRP levels at 4.5 mg/L. He experienced joint pain and had a sedentary lifestyle. Blood tests showed elevated LDL cholesterol at 160 mg/dL.
Interventions:
Progress: After 16 weeks, Hs-CRP levels dropped to 2.8 mg/L, a 38% reduction. LDL cholesterol decreased to 130 mg/dL. The patient lost 8 kg, reducing BMI to 29 kg/m², and reported less joint pain.
Key takeaway: This case underscores the role of dietary changes and pharmacotherapy in managing inflammation and cardiovascular risk. The study's limitations include short follow-up duration and potential placebo effects from group sessions.
Hs Crp is included in our comprehensive biomarker panels, processed at CLIA-certified Quest Diagnostics locations nationwide.
Foundation for a full basic health picture.
Deeper metabolic and nutritional insights.
Comprehensive testing for lifelong health.
Medical Disclaimer: This content is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with any questions about a medical condition or treatment. Do not disregard professional medical advice or delay seeking it because of information presented here.
Every insight is grounded in vetted literature—browse the key references behind this intelligence.
Serum levels of galanin-like peptide and alarin are highly correlated with polycystic ovary syndrome.
Liu M, Zhang X, Sun Z, Wang H, Sun X, Zhang W
Scientific reports
2025
DOI: 10.1038/s41598-025-93354-1
PMID: 40119152
Serum levels of galanin-like peptide and alarin are highly correlated with polycystic ovary syndrome. Published in Scientific reports 2025.
Exploring the Relationships between Sex Hormones and Abdominal Muscle Area and Radiodensity in Postmenopausal Women: Insights from the Multi-Ethnic Study of Atherosclerosis.
Osmancevic A, Allison M, Miljkovic I, Vella CA, Ouyang P, Trimpou P, Daka B
Maturitas
2025
DOI: 10.1016/j.maturitas.2025.108197
PMID: 39827737
Exploring the Relationships between Sex Hormones and Abdominal Muscle Area and Radiodensity in Postmenopausal Women: Insights from the Multi-Ethnic Study of Atherosclerosis. Published in Maturitas 2025. Title indicates female cohort signal (title level).
Peripheral Inflammation as a Biomarker of Disease Activity in Relapsing-Remitting MS.
Abdullah AH
Neuro-Signals
2025
DOI: 10.33594/000000814
PMID: 40977247
Peripheral Inflammation as a Biomarker of Disease Activity in Relapsing-Remitting MS. Published in Neuro-Signals 2025.
Differences and clinical significance of liver - kidney function parameters, inflammatory markers and peripheral blood T lymphocyte subsets in patients with HBV - related acute - on - chronic liver failure.
Dou Y, Zhang L, Wang H
BMC gastroenterology
2025
DOI: 10.1186/s12876-025-04112-6
PMID: 41013248
Differences and clinical significance of liver - kidney function parameters, inflammatory markers and peripheral blood T lymphocyte subsets in patients with HBV - related acute - on - chronic liver failure. Published in BMC gastroenterology 2025. Reference for ALT clinical interpretation.
Clinical characteristics of mycoplasma pneumoniae pneumonia in children with 23 S rRNA mutations in domain V and exploration of the timing of glucocorticoid therapy.
Shen R, Zhou L, Chen Y, Chen Y, Yang S
BMC infectious diseases
2025
DOI: 10.1186/s12879-025-11584-0
PMID: 41013328
Clinical characteristics of mycoplasma pneumoniae pneumonia in children with 23 S rRNA mutations in domain V and exploration of the timing of glucocorticoid therapy. Published in BMC infectious diseases 2025.